GlobeNewswire·Jun 30, 2026, 4:15 PM ET

Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape

Amarin Corporation applauds FDA approval of injectable APOC3 therapies for severe hypertriglyceridemia (sHTG) while emphasizing VASCEPA as a critical first-line option.
CEO Aaron Berg highlights that VASCEPA delivers a 33% median reduction in triglyceride levels without increasing LDL cholesterol.
A significant cost disparity exists between VASCEPA (~$4,200 annual wholesale acquisition cost) & new injectable APOC3 therapies (~$40,000 annual cost).
Payors & pharmacy benefit managers may prioritize VASCEPA through step-therapy requirements due to the high cost of alternative injectable treatments.
VASCEPA has been prescribed over 30 million times globally & is the only FDA-approved therapy proven to reduce cardiovascular event risk by 25% in high-risk patients.
The 2026 ACC/AHA/Multisociety Dyslipidemia Guideline reaffirms the role of established therapies like VASCEPA in managing elevated triglycerides.
VASCEPA is indicated as an adjunct to statins to reduce cardiovascular risk or as an adjunct to diet to lower triglycerides in patients with severe hypertriglyceridemia.
Safety data indicates VASCEPA is associated with increased risks of atrial fibrillation & bleeding compared to placebo.
Amarin states that while new therapies benefit specific high-risk patients, VASCEPA offers superior clinical & economic value for the majority of the sHTG population.